

Disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (“TC”)	Orchid Pharma Limited		
Name(s) of the acquirer / seller and Persons Acting in Concert (PAC) with the acquirer / seller	Seller (i) Massachusetts Institute of Technology (“MIT”) (ii) 238 Plan Associates LLC (“238 Plan”) PAC MIT and 238 Plan are persons acting in concert with each other		
Whether the acquirer / seller belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	The National Stock Exchange of India Limited BSE Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Before the acquisition / disposal under consideration, holding of:			
a) Shares carrying voting rights			
(i) MIT	2,321,000	4.58%	4.58%
(ii) 238 Plan	611,000	1.20%	1.20%
b) Shares in the nature of encumbrance (pledge/ lien / non-disposal undertaking / others)	NA	NA	NA
c) Voting rights (VR) otherwise than by shares	NA	NA	NA
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NA	NA	NA
e) Total (a+b+c+d)	2,932,000	5.78%	5.78%
Details of acquisition / sale			
a) Shares carrying voting rights acquired / sold			
(i) MIT	500,000	0.99%	0.99%
(ii) 238 Plan	500,000	0.99%	0.99%
b) VRs acquired / sold otherwise than by shares	NA	NA	NA
c) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC	NA	NA	NA

(specify holding in each category) acquired / sold			
d) Shares encumbered / invoked / released by the acquirer	NA	NA	NA
e) Total (a+b+c+/-d)	1,000,000	1.97%	1.97%
After the acquisition / sale, holding of:			
a) Shares carrying voting rights			
(i) MIT	1,821,000	3.59%	3.59%
(ii) 238 Plan	111,000	0.22%	0.22%
b) Shares encumbered with the acquirer	NA	NA	NA
c) VRs otherwise than by shares	NA	NA	NA
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NA	NA	NA
e) Total (a+b+c+d)	1,932,000	3.81%	3.81%
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Sale of shares on the open market		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	Various sales between 11 December 2023 and 15 December 2023. The date of sale on which the disclosure threshold was triggered was 15 December 2023.		
Equity share capital / total voting capital of the TC before the said acquisition / sale	50,719,105 equity shares of face value INR 10 each, amounting to INR 507,191,050		
Equity share capital / total voting capital of the TC after the said acquisition / sale	50,719,105 equity shares of face value INR 10 each, amounting to INR 507,191,050		
Total diluted share / voting capital of the TC after the said acquisition / sale	50,719,105 equity shares of face value INR 10 each, amounting to INR 507,191,050		

Note: All shareholding percentages mentioned above have been rounded off to 2 decimal places.

(*) Total share capital / voting capital to be taken as per the latest filing done by the Target Company to the Stock Exchange under Regulation 31 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

[Signature page follows]

For MASSACHUSETTS INSTITUTE OF TECHNOLOGY


For 238 PLAN ASSOCIATES LLC

DocuSigned by:

3FFCCD74E1A24EA...

Seth Alexander

Authorized Signatory

DocuSigned by:

3FFCCD74E1A24EA...

Seth Alexander

Authorized Signatory

Place : Cambridge, MA USA

Date : 18 December 2023